Skip to main content

Advertisement

SpringerLink
Log in

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose: The objectives of these analyses were to (1) develop a semimechanistic-physiologic population pharmacokinetic/pharmacodynamic (PK/PD) model to describe neutropenic response to pemetrexed and to (2) identify influential covariates with respect to pharmacodynamic response. Patients and methods: Data from 279 patients who received 1,136 treatment cycles without folic acid or vitamin B12 supplementation during participation in one of eight phase II cancer trials were available for analysis. Starting doses were 500 or 600 mg pemetrexed per m2 body surface area (BSA), administered as 10-min intravenous infusions every 21 days (1 cycle). The primary analyses included 105 patients (279 cycles) for which selected covariates—including vitamin deficiency marker data (i.e., homocysteine, cystathionine, methylmalonic acid, and methylcitrate [I, II, and total] plasma concentrations)—were available. Classical statistical multivariate regression analyses and a semimechanistic-physiologic population PK/PD model were used to evaluate neutropenic response to single-agent pemetrexed administration. Results: The timecourse of neutropenia following single-agent pemetrexed administration was adequately described by a semimechanistic-physiologic model. Population estimates for system-based model parameters (i.e., baseline neutrophil count, mean transit time, and the feedback parameter), which mathematically represent current understanding of the process and physiology of hematopoiesis, were consistent with previously reported values. The population PK/PD model included homocysteine, cystathionine, albumin, total protein, and BSA as covariates relative to neutropenic response. Conclusion: These results support the programmatic decision to introduce folic acid and vitamin B12 supplementation during pemetrexed clinical development as a means of normalizing patient homocysteine levels, thereby managing the risk of severe neutropenia secondary to pemetrexed administration. The current results also suggest that the addition of vitamin B6 supplementation to normalize patient cystathionine levels may further decrease the incidence of grade 4 neutropenia following pemetrexed administration. The results also suggest the use of folic acid as a means of lessening hematologic toxicity following administration of cytotoxic agents other than antifolates.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Adjei AA (2003) Pemetrexed (Alimta): a novel multitargeted antifolate agent. Expert Rev Anticancer Ther 3:145–156

    Article  PubMed  CAS  Google Scholar 

  2. Alati T, Shih C, Pohland RC, Lantz FJ, Grindey GB (1992) Evaluation of the mechanism(s) of inhibition of the toxicity, but not the antitumor activity of lomotrexol (DDATHF) by folic acid. Proc Am Assoc Cancer Res 33:407

    Google Scholar 

  3. Alimta Drug Approval Package, Medical Review. Food and Drug Administration Web site. Available at: http://www.fda.gov/cder/foi/nda/2004/21-462.pdf_Alimta_Medr_P6.pdf. Page 257. Accessed September 20, 2004

  4. Allen RH, Stabler SP, Savage DG, Lindenbaum J (1993) Metabolic abnormalities in cobalamin (vitamin B12) and folate deficiency. FASEB J 7:1344–1353

    PubMed  CAS  Google Scholar 

  5. Bajetta E, Celio L, Buzzoni R et al (2003) Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 14:1543–1548

    Article  PubMed  CAS  Google Scholar 

  6. Beal SL, Sheiner LB (1982) Estimating population kinetics. Crit Rev Biomed Eng 8:195–222

    PubMed  CAS  Google Scholar 

  7. Beal SL, Sheiner LB (1988) Heterskedastic nonlinear regression. Technometrics 30:327–338

    Article  Google Scholar 

  8. Beal SL, Sheiner LB (1992) NONMEM user’s guide NONMEM project group. University of California, San Francisco

    Google Scholar 

  9. Branda RF, Nigels E, Lafayette AR, Hacker M (1998) Nutritional folate status influences the efficacy and toxicity of chemotherapy in rats. Blood 92:2471–2476

    PubMed  CAS  Google Scholar 

  10. Branda RF, Chen Z, Brooks EM, Naud SJ, Trainer TD, McCormack JJ (2002) Diet modulates the toxicity of cancer chemotherapy in rats. J Lab Clin Med 140:358–368

    Article  PubMed  CAS  Google Scholar 

  11. Branda RF, Naud SJ, Brooks EM, Chen Z, Muss H (2004) Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy-induced mucositis and neutropenia. Cancer 101:1058–1064

    Article  PubMed  CAS  Google Scholar 

  12. Carmel R, Jacobsen DW (2001) (eds) Homocysteine in health and disease. Cambridge University Press, New York

    Google Scholar 

  13. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41

    PubMed  CAS  Google Scholar 

  14. Cripps C, Burnell M, Jolivet J et al (1999) Phase II study of first-line LY231514 (multitargeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 10:1175–1179

    Article  PubMed  CAS  Google Scholar 

  15. Ette EI (1997) Stability and performance of a population pharmacokinetic model. J Clin Pharmacol 37:486–495

    PubMed  CAS  Google Scholar 

  16. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO (2002) Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 20:4713–4721

    Article  PubMed  Google Scholar 

  17. Goedhals L, van Wijk AL (1998) MTA (LY231514) in advanced carcinoma of the cervix. Ann Oncol 9(suppl 4):70

    Article  Google Scholar 

  18. Grindey GB, Alati T, Shih C (1991) Reversal of the toxicity but not the antitumor activity of lometrexol by folic acid. Proc Am Assoc Cancer Res 32:324

    Google Scholar 

  19. Grindey GB, Shih C, Barnett CJ et al (1992) LY231514, a novel pyrrolopyrimidine antifolate that inhibits thymidylate synthase (TS). Proc Am Assoc Cancer Res 33:411

    Google Scholar 

  20. Hanauske AR, Chen V, Paoletti P, Niyikiza C (2001) Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 6:363–373

    Article  PubMed  CAS  Google Scholar 

  21. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597

    Article  PubMed  CAS  Google Scholar 

  22. Homocysteine Lowering Trialists’ Collaboration (1998) Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 316:894–898

    Google Scholar 

  23. Laohavinij S, Wedge SR, Lind MJ et al (1996) A phase I clinical study of the antipurine antifolate lomotrexol (DDATHF) given with oral folic acid. Invest New Drugs 14:325–335

    Article  PubMed  CAS  Google Scholar 

  24. Latz JE, Chaudhary A, Ghosh A, Johnson RD (2006) Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients. Cancer Chemother Pharmacol 57. DOI 10.1007/s00280-005-0036-1

  25. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD (2006) Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57. DOI 10.1007/s00280-005-0035-2

  26. Maas H (2001) Development of a semi-physiological population PK/PD model of hematological toxicity: evaluation of across-drug consistency. MSc Thesis. Uppsala University. Uppsala, Sweden

  27. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I (1991) Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 146:3032–3037

    PubMed  CAS  Google Scholar 

  28. Maes M, Stevens W, Scharpe S et al (1994) Seasonal variation in peripheral blood leukocyte subsets and in serum interleukin-6 and soluble interleukin-2 and −6 receptor concentrations in normal volunteers. Experientia 50:821–829

    Article  PubMed  CAS  Google Scholar 

  29. Mandema JW, Verotta D, Sheiner LB (1992) Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 20:511–528

    Article  PubMed  CAS  Google Scholar 

  30. McKenzie SB (1996) Textbook of hematology. Williams and Wilkins, Baltimore, pp 22–29, pp 58–67

  31. Mentre F, Ebelin ME (1997) Validation of population pharmacokinetic/pharmacodynamic analyses: review of proposed approaches. In: Balant LP, Aarons L (eds) The population approach: measuring and managing variability in response, concentration and dose. Commission of the European Communities, Brussels, pp 147–160

    Google Scholar 

  32. Miller KD, Picus J, Blanke C et al (2000) Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 11:101–103

    Article  PubMed  CAS  Google Scholar 

  33. Moran RG (1999) Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. Semin Oncol 26(2 suppl 6):24–32

    PubMed  CAS  Google Scholar 

  34. Niyikiza C, Baker SD, Seitz DE et al (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545–552

    PubMed  CAS  Google Scholar 

  35. Niyikiza C, Hanauske AR, Rusthoven JJ et al (2002) Pemetrexed safety and dosing strategy. Semin Oncol 29(6 Suppl 18):24–29

    PubMed  Google Scholar 

  36. Odamaki M, Kato A, Kumagai H, Hishida A (2004) Counter-regulatory effects of procalcitonin and indoxyl sulphate on net albumin secretion by cultured rat hepatocytes. Nephrol Dial Transplant 19:797–804

    Article  PubMed  CAS  Google Scholar 

  37. O’Dwyer PJ, Nelson K, Thornton DE (1999) Overview of phase II trials of MTA in solid tumors. Semin Oncol 26:99–104

    PubMed  CAS  Google Scholar 

  38. Paz-Ares L, Tabernero J, Moyano A et al (1999) Significant activity of the multitargeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a phase II trial. Eur J Cancer 35(suppl 2):S81

    Google Scholar 

  39. Pivot X, Raymond E, Laguerre B et al (2001) Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 85:649–655

    Article  PubMed  CAS  Google Scholar 

  40. Rinaldi DA, Kuhn JG, Burris HA et al (1999) A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 44:372–380

    Article  PubMed  CAS  Google Scholar 

  41. Rusthoven JJ, Eisenhauer E, Butts C et al (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194–1199

    PubMed  CAS  Google Scholar 

  42. Sandström M, Lindman H, Nygren P, Lidbrink E, Bergh J, Karlsson MO (2005) Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients. J Clin Oncol 23:413–421

    Article  PubMed  CAS  Google Scholar 

  43. SAS Institute Inc (1997) SAS/STAT software: changes and enhancements through release 6.12. Cary, NC: SAS Institute Inc

  44. Scagliotti GV, Shin DM, Kindler HL et al (2003) Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 21:1556–1561

    Article  PubMed  CAS  Google Scholar 

  45. Shargel L, Yu ABC (1985) Applied biopharmaceutics, 2nd edn. Appleton-Century-Crofts, Norwalk, pp 310–312

    Google Scholar 

  46. Sheiner LB (1986) Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals. J Pharmacokinet Biopharm 14:539–555

    Article  PubMed  CAS  Google Scholar 

  47. Sheiner LB, Steimer JL (2000) Pharmacokinetic/pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67–95

    Article  PubMed  CAS  Google Scholar 

  48. Shih C, Gosset L, Gates S et al (1996) LY231514 and its polyglutamates exhibit potent inhibition against both human dihydrofolate reductase (DHFR) and thymidylate synthase (TS): multiple folate enzyme inhibition. Ann Oncol 7(Suppl 1):85

    PubMed  Google Scholar 

  49. Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ (2001) Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2:47–51

    Article  PubMed  CAS  Google Scholar 

  50. Stabler SP, Lindenbaum J, Savage DG, Allen RH (1993) Elevation of serum cystathionine levels in patients with cobalamin and folate deficiency. Blood 81:3404–3413

    PubMed  CAS  Google Scholar 

  51. Sun H, Fadiran EO, Jones CD et al (1999) Population pharmacokinetics. A regulatory perspective. Clin Pharmacokinet 37: 41–58

    Article  PubMed  CAS  Google Scholar 

  52. Suwa T, Hogg JC, English D, Van Eeden SF (2000) Interleukin-6 induces demargination of intravascular neutrophils and shortens their transit in marrow. Am J Physiol Heart Circ Physiol 279:H2954–H2960

    PubMed  CAS  Google Scholar 

  53. Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636–2644

    Article  PubMed  CAS  Google Scholar 

  54. Wedge SR, Laohavinij S, Taylor GA, Boddy A, Calvert AH, Newell DR (1995) Clincial pharmacokinetics of the antipurine antifolate (6R)-5,10- dideaza-5,6,7,8-tetrahydrofolic acid (Lomotrexol) administered with an oral folic acid supplement. Clin Cancer Res 1:1479–1486

    PubMed  CAS  Google Scholar 

  55. Yoshioka M, Mori Y, Miyazaki S, Miyamoto T, Yokomizo Y, Nakajima Y (1999) Biological functions of recombinant bovine interleukin 6 expressed in a baculovirus system. Cytokine 11:863–868

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the following individuals for their assistance with the conduct of these analyses and preparation of this manuscript: Dinesh Dealwis, Lena Friberg, and S Thomas Forgue for their insightful scientific comments; Mary Brandes Dugan and Pete Fairfield for their scientific writing and editorial support; and, David B. Radtke for operations and project management support.

Author information

Authors and Affiliations

  1. Global Pharmacokinetics, Pharmacodynamics, and Trial Simulation, Lilly Research Laboratories, Lilly Corporate Center, Eli Lilly and Company, Indianapolis, IN, 46285, USA

    Jane E Latz & Atalanta Ghosh

  2. Uppsala University, Uppsala, Sweden

    Mats O Karlsson

  3. McMaster University, Hamilton, ON, Canada

    James J Rusthoven

  4. Proctor & Gamble Pharmaceuticals, Cincinnati, OH, USA

    Robert D Johnson

Authors
  1. Jane E Latz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mats O Karlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James J Rusthoven
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Atalanta Ghosh
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert D Johnson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jane E Latz.

Additional information

James J Rusthoven, Robert D Johnson were employees of Eli Lilly and Company, Indianapolis, USA, at the time this work was completed

Rights and permissions

Reprints and permissions

About this article

Cite this article

Latz, J.E., Karlsson, M.O., Rusthoven, J.J. et al. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 57, 412–426 (2006). https://doi.org/10.1007/s00280-005-0077-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-005-0077-5

Keywords

Search

Navigation